BioPharma Resources

Drug Trial Radar · NCT05077904

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Dec 7, 2021

Primary completion

Mar 29, 2027

Study completion Mar 29, 2027

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Oct 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.

Conditions

  • Stereotypical Prolonged Seizures

Interventions

  • Staccato alprazolamDrug

    Route of administration: Inhalation Participants will receive one dose of Staccato alprazolam during the Treatment Period.

  • PlaceboOther

    Route of administration: Inhalation Participants will receive one dose of placebo during the Treatment Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment success for the treated seizure within 90 seconds after investigational medicinal product (IMP) administrationTime frame: From start of IMP treatment through 6 hours
  2. Treatment success for the treated seizure with no recurrence up to 2 hoursTime frame: From start of IMP treatment through 2 hours

Locations

183 sites in 13 countries. Site status is shown where the registry gives one.

  • Ep0162 50506

    Phoenix, Arizona · Recruiting

  • Ep0162 50720

    Scottsdale, Arizona · Recruiting

  • Ep0162 50494

    Little Rock, Arkansas · Completed

  • Ep0162 50118

    Downey, California · Recruiting

  • Ep0162 50416

    La Jolla, California · Recruiting

  • Ep0162 50702

    Long Beach, California · Recruiting

  • Ep0162 50505

    Los Angeles, California · Withdrawn

  • Ep0162 50492

    Orange, California · Completed

  • Ep0162 50722

    Poway, California · Withdrawn

  • Ep0162 50716

    Sacramento, California · Recruiting

  • Ep0162 50367

    New Haven, Connecticut · Completed

  • Ep0162 50088

    Washington D.C., District of Columbia · Recruiting

  • Ep0162 50721

    Boca Raton, Florida · Withdrawn

  • Ep0162 50515

    Gulf Breeze, Florida · Completed

  • Ep0162 50508

    Jacksonville, Florida · Recruiting

  • Ep0162 50342

    Jacksonville, Florida · Recruiting

  • Ep0162 50199

    Miami, Florida · Recruiting

  • Ep0162 50676

    Miami, Florida · Recruiting

  • Ep0162 50509

    Orlando, Florida · Completed

  • Ep0162 50703

    Rockledge, Florida · Recruiting

  • Ep0162 50308

    Tampa, Florida · Recruiting

  • Ep0162 50323

    Honolulu, Hawaii · Recruiting

  • Ep0162 50512

    Boise, Idaho · Recruiting

  • Ep0162 50493

    Chicago, Illinois · Recruiting

  • Ep0162 50375

    Springfield, Illinois · Withdrawn

  • Ep0162 50504

    Fort Wayne, Indiana · Recruiting

  • Ep0162 50561

    Lexington, Kentucky · Withdrawn

  • Ep0162 50395

    New Orleans, Louisiana · Withdrawn

  • Ep0162 50517

    New Orleans, Louisiana · Recruiting

  • Ep0162 50093

    Baltimore, Maryland · Withdrawn

  • Ep0162 50488

    Bethesda, Maryland · Withdrawn

  • Ep0162 50615

    Boston, Massachusetts · Recruiting

  • Ep0162 50047

    Boston, Massachusetts · Completed

  • Ep0162 50110

    Ann Arbor, Michigan · Completed

  • Ep0162 50507

    St Louis, Missouri · Recruiting

  • Ep0162 50499

    Las Vegas, Nevada · Withdrawn

  • Ep0162 50626

    Neptune City, New Jersey · Withdrawn

  • Ep0162 50299

    New Brunswick, New Jersey · Recruiting

  • Ep0162 50497

    Buffalo, New York · Recruiting

  • Ep0162 50625

    New Hyde Park, New York · Completed

Showing 40 of 183 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.